<DOC>
	<DOCNO>NCT01363440</DOCNO>
	<brief_summary>The purpose study determine efficacy Intravitreal Aflibercept Injection ( IAI ; EYLEA® ; BAY86-5321 ) best correct visual acuity ( BCVA ) assess early treatment diabetic retinopathy study ( ETDRS ) chart patient diabetic macular edema ( DME ) central involvement .</brief_summary>
	<brief_title>Study Intravitreal Aflibercept Injection ( IAI ; EYLEA® ; BAY86-5321 ) Patients With Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<criteria>The following abbreviated list inclusion criterion : Adults ≥ 18 year type 1 2 diabetes mellitus Decrease vision determine primarily result DME study eye BCVA ETDRS letter score 73 24 ( 20/40 20/320 ) study eye The following abbreviated list exclusion criterion : Laser photocoagulation ( panretinal macular ) study eye within 90 day day 1 Previous use intraocular periocular corticosteroid study eye within 120 day day 1 Previous treatment antiangiogenic drug study eye ( pegaptanib sodium , bevacizumab , ranibizumab , etc . ) within 90 day day 1 Active proliferative diabetic retinopathy ( PDR ) study eye Uncontrolled diabetes mellitus Only 1 functional eye even eye otherwise eligible study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Diabetic Macular Edema</keyword>
	<keyword>Diabetic Retinopathy</keyword>
</DOC>